Cerus Company Description

Cerus Corporation operates as a biomedical products company.

The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.

Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced.

It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally.

The company was incorporated in 1991 and is headquartered in Concord, California.

Cerus Corporation

Country	United States
Founded	1991
Industry	Orthopedic, Prosthetic, and Surgical Appliances and Supplies
Employees	630
CEO	William Greenman

Contact Details

Address: 1220 Concord Avenue Concord, Delaware 94520 United States
Phone	925 288 6000
Website	cerus.com

Stock Details

Ticker Symbol	CU2
Exchange	Frankfurt Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	3842

Key Executives

Name	Position
William Greenman	Chief Executive Officer
Kevin Green	Chief Financial Officer
Vivek Jayaraman	Chief Operating Officer
Timothy Lee	Head of Investor Relations